These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 33139290)

  • 21. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remdesivir: Quo vadis?
    De Clercq E
    Biochem Pharmacol; 2021 Nov; 193():114800. PubMed ID: 34678228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
    Brooks KM; Baltrusaitis K; Clarke DF; Nachman S; Jao J; Purswani MU; Agwu A; Beneri C; Deville JG; Powis KM; Stek AM; Eke AC; Shapiro DE; Capparelli E; Greene E; George K; Yin DE; Jean-Philippe P; Chakhtoura N; Bone F; Bacon K; Johnston B; Reding C; Kersey K; Humeniuk R; Best BM; Mirochnick M; Momper JD;
    J Infect Dis; 2024 Oct; 230(4):878-888. PubMed ID: 38839047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir: First Approval.
    Lamb YN
    Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
    Taha HR; Keewan N; Slati F; Al-Sawalha NA
    Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
    Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
    West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
    Sun D
    AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
    SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.
    Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL
    PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
    Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
    Yan VC; Muller FL
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2.
    Xie Y; Yin W; Zhang Y; Shang W; Wang Z; Luan X; Tian G; Aisa HA; Xu Y; Xiao G; Li J; Jiang H; Zhang S; Zhang L; Xu HE; Shen J
    Cell Res; 2021 Nov; 31(11):1212-1214. PubMed ID: 34584244
    [No Abstract]   [Full Text] [Related]  

  • 37. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
    Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.